Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
Tigecycline is a novel 9-t-butylglycylamido derivative of minocycline that has demonstrated activity against a variety of Gram-positive and -negative bacterial pathogens. In vitro activity of tigecycline and comparator agents was determined for 3498 recent (2000-2003) strains of Staphylococcus aureus recovered from patients with either nosocomial or community-acquired infections. Oxacillin-susceptible and -resistant S. aureus from both patient populations displayed identical results for tigecycline (MIC(50) and MIC(90) results at 0.25 and 0.5 mg/L, respectively) and all strains were inhibited by 1 mg/L or less. While co-resistances to other antimicrobial classes were present in oxacillin-resistant strains, susceptibility to tigecycline remained unaffected, making the compound an attractive candidate for treatment of serious hospital as well as community-acquired staphylococcal infections.
Fritsche
Thomas R
TR
The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. ronald-jones@jmilabs.com
Jones
Ronald N
RN
D017714:Community-Acquired Infections / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology; D024881:Drug Resistance, Bacterial / Q000502:physiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D010068:Oxacillin / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects*; D000078304:Tigecycline
D000078304:Tigecycline; D008911:Minocycline; D010068:Oxacillin